Celgene Corporation company logo

# 1st Gen Model Celgene Corporation Pharmaceutical preparations

Subscribe >> Deal exit on
July 21, 2017
71.43% successful of 70 deals
$137.74 Last close price
at 21-jul-2017

CELG

Model's trade recommendations -7.99% Return for period

10.58% Annual return

$105.41B Market Cap

β 1.89  

CELG

Model (following trade recommendations)

CELG

Underlying stock

S&P 500

Index
Return for period -7.99%
2.55%
1.78%
52wk return 3.66%
28.11%
16.82%
52wk Range
97.63—137.74
2000.54—2399.63
Sortino ratio 1.05
Sharpe ratio 0.78
Norm. RMSE 0.71%
Downside risk 10.11%
Volatility 13.61%
  • STRONG BUY Analysts consensus recommendation

Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Celgene Corporation (CELG) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for CELG model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 773M
P/E 24.06
Shares Outstanding 781M
% Held by Insiders 0.95%
% Held by Institutions 78.16%
EPS (last reported FY) $5.18
EPS (last reported Q) $1.53
EPS, estimated (last reported Q) $1.47
Total revenues $11 B
Net income $2 B